Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03824951 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 iCAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03731390 Not yet recruiting - Lymphoma Clinical Trials

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Start date: November 2018
Phase: Phase 1
Study type: Interventional

This is a Phase I clinical study for evaluating the safety, pharmacokinetics, and preliminary efficacy of repeated doses, dose escalation of GR1405 injection in patients with advanced solid tumor or lymphoma

NCT ID: NCT03719989 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EPIC
Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

This phase II clinical trial aims at evaluating the efficacy and safety of azacitidine followed by rituximab-GDP immunochemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients who were treated with from 1 to 4 lines of prior therapies for relapsed/refractory DLBCL wee eligible. azacitidine will be treated one week prior to conventional rituximab-gemcitabine, dexamethasone, cisplatin (R-GDP) immunochemotherapy. Patients will be treated every 21 days as one cycle, and up to 6 cycles. The primary endpoint of this study is objective response rate according to the Lugano response criteria for non-Hodgkin lymphoma, and secondary endpoints are safety, complete response, progression-free survival, and overall survival.

NCT ID: NCT03701022 Not yet recruiting - NK/T-cell Lymphoma Clinical Trials

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Start date: October 20, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 combined with Apatinib in subjects with relapsed or refractory NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.

NCT ID: NCT03692767 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03690310 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 CAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03602131 Not yet recruiting - Hodgkin Lymphoma Clinical Trials

Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

This study is to explore the efficacy and safety of ChiCGB conditioning therapy in patients with high-risk Hodgkin and non-Hodgkin lymphoma.

NCT ID: NCT03598959 Not yet recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma

Tofacitinib Combined With Chidamide in R/R ENKTCL

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

This study is to explore the efficacy and safety of tofacitinib combined with chidamide in patients with relapsed and refractory extranodal NK/T cell lymphoma.

NCT ID: NCT03553537 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphoma

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Start date: June 2018
Phase: Phase 3
Study type: Interventional

Primary objective of the study is to compare the efficacy and safety of decitabine plus CHOP (D-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL).

NCT ID: NCT03410004 Not yet recruiting - Experimental Clinical Trials

Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Start date: January 25, 2018
Phase: Phase 2
Study type: Interventional

Study of Chidamide as a single-agent treatment for patients with relapse or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)